Get the Stockscreener App
37.23
0.85%
-0.32
After Hours:
37.42
0.19
+0.51%
Tg Therapeutics Inc stock is traded at $37.23, with a volume of 2.39M.
It is down -0.85% in the last 24 hours and up +20.49% over the past month.
See More
Previous Close:
$37.55
Open:
$38.15
24h Volume:
2.39M
Relative Volume:
1.03
Market Cap:
$4.54B
Revenue:
$264.79M
Net Income/Loss:
$-14.36M
P/E Ratio:
-338.45
EPS:
-0.11
Net Cash Flow:
$-28.11M
1W Performance:
+6.04%
1M Performance:
+20.49%
6M Performance:
+60.54%
1Y Performance:
+135.04%
1-Day Range:
$36.82
$38.70
1-Week Range:
$34.34
$40.31
52-Week Range:
$12.93
$40.31
Tg Therapeutics Inc Stock (TGTX) Company Profile
Name
Tg Therapeutics Inc
Sector
Industry
Phone
(212) 554-4484
Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
37.23 | 4.54B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-29-24 | Initiated | TD Cowen | Buy |
| Aug-02-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-26-23 | Resumed | Jefferies | Buy |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-19-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-01-20 | Initiated | JP Morgan | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Initiated | Evercore ISI | Outperform |
| Jan-17-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Sep-25-18 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-01-17 | Resumed | B. Riley FBR, Inc. | Buy |
| Nov-14-17 | Resumed | H.C. Wainwright | Buy |
| Apr-25-17 | Initiated | Jefferies | Buy |
| Mar-06-17 | Reiterated | FBR & Co. | Outperform |
| Oct-06-16 | Resumed | Brean Capital | Buy |
| May-27-16 | Initiated | SunTrust | Buy |
| Dec-01-15 | Initiated | FBR Capital | Outperform |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| Aug-12-15 | Resumed | H.C. Wainwright | Buy |
| Jun-19-15 | Reiterated | Brean Capital | Buy |
| Dec-11-14 | Reiterated | ROTH Capital | Buy |
| Dec-10-14 | Reiterated | ROTH Capital | Buy |
View All
Tg Therapeutics Inc Stock (TGTX) Latest News
TG Therapeutics: Exciting Briumvi Performance, Looking To Re-Enter (NASDAQ:TGTX) - Seeking Alpha
10 Best Performing Growth Stocks in 2025 - Insider Monkey
Proficio Capital Partners LLC Buys Shares of 10,174 TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
TG Therapeutics call volume above normal and directionally bullish - TipRanks
Smartleaf Asset Management LLC Has $60,000 Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
TG Therapeutics (NasdaqCM:TGTX) Surges 28% Following US$23 Million Net Income Turnaround - Yahoo Finance
Bilibili, MARA And ZEEKR Are Among Top 8 Mid-Cap Gainers Last Week (Mar 3-Mar 7): Are The Others In Your Portfolio? - Benzinga
Bank of New York Mellon Corp Increases Stake in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
Q2 Earnings Forecast for TG Therapeutics Issued By B. Riley - Defense World
TGTX Surges on Strong Q4 Results and Briumvi Success - GuruFocus.com
Why TG Therapeutics Stock Was Soaring This Week - Nasdaq
Why TG Therapeutics Shares Are Soaring Now - TipRanks
Retail Bets TG Therapeutics Stock Can Sustain Post-Earnings Gains Throughout The Week - MSN
TG Therapeutics Announces Schedule of Data Presentations - GlobeNewswire
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting - Yahoo Finance
Q1 Earnings Forecast for TG Therapeutics Issued By B. Riley - Defense World
This Biotech Stock Hits Buy Point After Earnings Burst - MSN
HC Wainwright Reaffirms “Buy” Rating for TG Therapeutics (NASDAQ:TGTX) - Defense World
TG Therapeutics FY2025 EPS Estimate Boosted by HC Wainwright - Defense World
Why TG Therapeutics, Inc. (TGTX) Surged On Monday? - MSN
TG Therapeutics, Inc. (NASDAQ:TGTX) Holdings Decreased by Private Advisor Group LLC - Defense World
TG Therapeutics (NASDAQ:TGTX) Upgraded by StockNews.com to Hold Rating - Defense World
TG Therapeutics (NASDAQ:TGTX) Shares Up 5.2% After Earnings Beat - Defense World
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2024 Earnings Call Transcript - MSN
TG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX) - Defense World
TG Therapeutics, A New Leaderboard Stock, Skyrockets 17% On Sales Beat, Bullish Guide - MSN
TG Therapeutics stock soars to 52-week high of $36.89 By Investing.com - Investing.com South Africa
TG Therapeutics stock soars to 52-week high of $36.89 - Investing.com India
Cautious Outlook on TG Therapeutics Amid Competitive Pressures and Overvaluation Concerns - TipRanks
B. Riley Raises Price Target on TG Therapeutics to $53 From $38, Keeps Buy Rating -March 04, 2025 at 08:05 am EST - Marketscreener.com
H.C. Wainwright maintains TG Therapeutics stock Buy rating, $55 target - Investing.com India
H.C. Wainwright maintains TG Therapeutics stock Buy rating, $55 target By Investing.com - Investing.com UK
Strong Financial Performance and Promising Outlook Drive Buy Rating for TG Therapeutics - TipRanks
TG Therapeutics stock soars on Overweight rating at Cantor By Investing.com - Investing.com Canada
Exploring 3 High Growth Tech Stocks In The US Market - Yahoo Finance
Company News for Mar 4, 2025 - Yahoo Finance
TG Therapeutics Inc (TGTX) Q4 2024 Earnings Call Highlights: Strong U.S. ... - Yahoo Finance
TG Therapeutics (NASDAQ:TGTX) Sees Large Volume Increase on Better-Than-Expected Earnings - Defense World
TG Therapeutics Reports Strong 2024 Financial Results and Outlook - TipRanks
TG Therapeutics Earnings Call: Strong Growth Amid Challenges - TipRanks
TG Therapeutics: Q4 Earnings Snapshot - CTPost
TG Therapeutics stock spikes on strong financials and optimism for its flagship drug - Mugglehead
TG Therapeutics soared 17% after earnings surprise - MSN
TG Therapeutics targets $525M BRIUMVI revenue in 2025 while advancing subcutaneous formulation and pivotal trials - MSN
Why This New Leaderboard Stock Just Skyrocketed 14% - Investor's Business Daily
TG Therapeutics: A Wonderful Hold (NASDAQ:TGTX) - Seeking Alpha
TG Therapeutics stock soars on Overweight rating at Cantor - Investing.com India
TG Therapeutics reports Q4 EPS 15c, consensus 17c - TipRanks
Earnings call transcript: TG Therapeutics Q4 2024 earnings beat forecasts By Investing.com - Investing.com Canada
Earnings call transcript: TG Therapeutics Q4 2024 earnings beat forecasts - Investing.com India
TG Therapeutics Soars Nearly 18% as Strong Q4 Results Fuel Growth Optimism - Yahoo Finance
Tg Therapeutics Inc Stock (TGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):